A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, Immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.
Read more at Pfizer News
Read More at Medical Xpress
Read More at Clinical Trails Arena
Updated General Eligibility Criteria
2021 Final Informed Consent Disclosure